Literature DB >> 22565190

Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome.

N Schweighofer1, E Lerchbaum, O Trummer, V Schwetz, S Pilz, T R Pieber, B Obermayer-Pietsch.   

Abstract

The polycystic ovary syndrome (PCOS), characterized by hyperandrogenism, is one of the most common hormonal disorders among premenopausal women and is associated with infertility, obesity, and insulin resistance. Accumulating evidence suggests a role of the blood coagulation factor gene F13A1 in obesity (GeneBank ID: NM_000129.3). The aim of this study was to investigate the association of intronic allelic variants of the F13A1 gene with PCOS susceptibility and metabolic parameters in lean and obese PCOS women. In a case-control study, we determined an intronic F13A1 single nucleotide polymorphism (SNP) (dbSNP ID: rs7766109) in 585 PCOS and 171 control women and tested for PCOS susceptibility and associations with anthropometric, metabolic and hormonal parameters. Genotype frequencies of the F13A1 SNP rs7766109 were equivalent in PCOS and control women. In PCOS women, F13A1 gene variants were significantly associated with body mass index (BMI) (p=0.013), systolic blood pressure (p=0.042), insulin response (AUCins) (p=0.015), triglycerides (TG) (p=0.001), and high density lipoprotein cholesterol (HDL) (p=0.012). In the subgroup of obese PCOS women free androgen index (FAI), free testosterone and sex hormone binding globulin (SHBG) as well as glucose measurements showed a significantly different pattern across F13A1 gene variants (p=0.043; p=0.039 and p=0.013, respectively). We report for the first time an association of the F13A1 SNP rs7766109 with BMI, androgens, and insulin resistance in PCOS women. Further studies are needed to confirm our findings and to evaluate whether F13A1 is causally involved in the pathogenesis of PCOS related metabolic and hormonal disturbances.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565190     DOI: 10.1016/j.gene.2012.04.050

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Authors:  Alice Albu; Serban Radian; Simona Fica; Carmen Gabriela Barbu
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

2.  Association study of polymorphism of FXIIIVal34Leu gene and polycystic ovary syndrome.

Authors:  Xuefeng Wang; Yue Yang; Yanbing Huang; Qiongyao Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  An Islet-Targeted Genome-Wide Association Scan Identifies Novel Genes Implicated in Cytokine-Mediated Islet Stress in Type 2 Diabetes.

Authors:  Poonam R Sharma; Aaron J Mackey; Eden A Dejene; James W Ramadan; Carl D Langefeld; Nicholette D Palmer; Kent D Taylor; Lynne E Wagenknecht; Richard M Watanabe; Stephen S Rich; Craig S Nunemaker
Journal:  Endocrinology       Date:  2015-05-27       Impact factor: 4.736

4.  Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population.

Authors:  Anindya Dasgupta; Aparna Khan; Ushasi Banerjee; Mrinalkanti Ghosh; Mrinal Pal; Kanika M Chowdhury; Sayantan Dasgupta
Journal:  Indian J Clin Biochem       Date:  2012-09-14

5.  Factor XIII-A transglutaminase deficient mice show signs of metabolically healthy obesity on high fat diet.

Authors:  Vamsee D Myneni; Aisha Mousa; Mari T Kaartinen
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

6.  Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules.

Authors:  Praveenkumar Devarbhavi; Lata Telang; Basavaraj Vastrad; Anandkumar Tengli; Chanabasayya Vastrad; Iranna Kotturshetti
Journal:  Reprod Biol Endocrinol       Date:  2021-02-23       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.